reported more than 30 % PD-L1 expression in CRC tumor tissue, further investigations in developing PD-L1/PD-1 based immunotherapy should focus on the cell-type-specific analysis of the tumor surrounding the stroma. This evidence concerns the gene PDCD1 and neoplasm.